(Q36114445)

12 August 2017

Tamoxifen--the treatment of choice. Why look for alternatives? (English)

1 reference

12 August 2017

1 reference

Baum M

1

1 reference

PMC publication ID

2062753

12 August 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

12 August 2017

4

1 reference

British Journal of Cancer

inferred from page(s)

published in

1 reference

12 August 2017

78 Suppl 4

1 reference

12 August 2017

1-4

1 reference

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Tamoxifen-associated eye disease. A review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Use of tamoxifen for breast cancer: twenty-eight years later

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Long term effects of tamoxifen on blood lipid values in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Endocrine therapy for advanced breast cancer: a review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062753

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

23 September 2018

1 reference

12 December 2020

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

12 December 2020

Endocrine therapy of advanced breast cancer

1 reference

12 December 2020

Detection of endometrial carcinoma and hyperplasia in asymptomatic women

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.753

1 reference

12 August 2017

1 reference

PMC publication ID

2062753

12 August 2017

PubMed publication ID

9741780

1 reference

PMC publication ID

2062753